Passy Muir Valve (PMV) in-line with a ventilator circuit - Use of - Clinical Guideline

Reference no.: CG-CLIN/4445/24

Contents

1. Introduction	Page 1-2
2. Aim and Purpose	Page 2-3
3. Definitions and Key Words	Page 3-4
4. Main Body of the Guidelines	Page 4-8
5. Hazards and Complications	Page 9
6.Linked Documents	Page 9
7. References	Page 10-11
8. Document Control	Page 12

1. Introduction

Communication difficulties are one of the biggest challenges for mechanically ventilated patients (Tembo, Higgins and Parker, 2015). With a tracheostomy in situ, air bypasses the upper trachea and oropharynx which prevents speech occurring (Bier, 2004). Impaired communication can lead to:

- Safety concerns
- Violation of patient rights
- Reduced quality of life
- Frustration
- Anger
- Withdrawal from interaction
- Reduced participation in treatment
- Increased incidence of delirium
- Increased incidence of preventable reversible events

(Magnus & Turkington 2006, Kunduk et al 2010, Freeman-Sanderson et al 2018).

The Passy Muir Tracheostomy & Ventilator Swallowing and Speaking Valve (PMV) is a biasclosed position, no-leak valve. When a patient has a tracheostomy with the cuff inflated, airflow is directed in and out through the tracheostomy tube and bypasses the upper airway. Using the Valve with the cuff deflated, allows a patient to breathe in through the tracheostomy tube and out through the upper airway (mouth and nose). The valve works by closing at the end of inspiration, which redirects airflow upwards through the vocal folds and upper airway, allowing phonation (Li et al 2021). Research has shown that this redirection of airflow offers patients numerous clinical benefits, including:

- Voice/speech production
- Improved swallowing
- Secretion management
- Improved oxygenation
- Restores subglottic pressure
- Restores positive airway pressure (PEEP)
- Facilitates weaning
- Reduce aspiration
- Facilitates decannulation
- Improves sense of smell
- Infection Control
- Improved quality of life
- (O'Connor et al, 2019 and 2021, Li et al 2021).

The Passy Muir® Valve (PMV) should be used in conjunction with manufacturers guidelines published at: www.passymuir.com/sites/default/files/pdf/resource_guide.pdf.

The Passy Muir® Valve 007 is designed to be inserted into the ventilator circuit for patients with a tracheostomy, offering patients who are unable to tolerate a tracheostomy mask trial the above benefits. Studies have shown that the use of speaking valves does not result in any significant lung de-recruitment or adverse cardiovascular events (Sutt et al 2016, O'Connor 2019 and 2021, Sutt et al 2017).

For long term patients, the use of the PMV has been shown to enhance the weaning process by conditioning the patient to breathe past the oropharynx, thus increasing the strength of the diaphragm, intercostals and other accessory muscles (Sutt et al, 2016). Using PMV in the ventilator circuit allows earlier vocalisation and swallowing, which has a significant positive impact on their quality of life (Bier, 2004, Sutt and King, 2016, O'Connor et al 2019).

2. Aim and Purpose

This guideline aims to support the utilisation of the PMV within the ventilator circuit (in-line PMV ventilation) to improve speech, swallowing and quality of life for tracheostomy patients who are unable to progress to PMV trials via the tracheostomy mask.

It aims to improve the consistency, earlier implementation and standardisation of in-line PMV ventilation, by providing an evidence-based practice guideline.

This clinical document applies to:

Staff group

- Nurses
- Physiotherapists
- Doctors
- Speech and Language Therapists

3. Definitions and Key words

Physio: Physiotherapist

SLT : Speech and Language Therapist

ICU: Intensive Care Unit

Tracheostomy: Opening created at the front of the trachea so a tube can be inserted to help with breathing.

Cuff: Part of a tracheostomy that can inflated to help reduce the risk of aspiration and to aid ventilation.

Tracoe: Tracheostomy brand

Portex: Tracheostomy brand

Subglottic suction port: part of certain tracheostomies with the primary function to allow removal of secretions lying above the cuff to prevent the risk of ventilator acquired pneumonia (VAP).

ENT: Ear, nose and throat department

Passy Muir Valve (PMV): one way valve that fits in line with the ventilator circuit, is bias closed and directs airflow through the larynx on expiration.

FNE: fibreoptic nasendoscopy

HCRs: health care records

Drager, Mindray: models of ventilators

PEEP: Peak end expiratory Pressure

PS: Pressure Support

CCS: Closed Circuit Suction

NIV: Non-invasive ventilation

WOB: Work of breathing

- FiO2: Fraction of inspired oxygen
- ASB: Assisted Spontaneous Breathing
- NG: Nasogastric
- NJ: Nasojejunal

4. Main body of Guidelines

Patient selection criteria:

- At least 72 hours post tracheostomy insertion.
- Patient over the age of 18.
- Alert patient who attempts to communicate, able to follow simple instructions and consents/agrees to the procedure.
- Agreement gained from managing Consultant.
- Off sedation
- Manageable chest and oral secretions
- PEEP of 10 or less
- Peak inspiratory pressure (PIP) less than 40
- ASB / pressure support less than 15.
- Respiratory rate less than 30

Contraindications:

- Less than 72 hours post insertion of current tube.
- Patient declines/refuses to consent.
- Suspected or confirmed upper airway obstruction.
- Unmanageable chest or oral secretions
- Medically unstable or not alert
- Recent head and neck surgery/laryngectomy
- Tracheostomy tube displaced or not in optimal position
- Ventilator requirements outside the parameters above

- Unable to tolerate cuff deflation
- Large size tracheostomy tube which limits airflow past the tube even with the cuff deflated. This should be assessed on a patient-to patient basis, but considered with all patients with a tracheostomy above size 8 needs to be discussed with the MDT.
- Bulbar palsy
- Sedated, paralysed, sleeping or comatose patients
- Severely reduced lung elasticity that may cause air trapping.

Equipment:

- PMV 007, aqua speaking valve
- Flexible catheter mount 22F-22M/15F
- 2 x 10ml syringe
- Cuff pressure gauge
- green straight connector size 22F/22F
- Closed suction circuit
- Yankauer suction tube

Staff required


- An ICU Consultant or a Senior Physiotherapist needs to be in attendance for the first attempt at using a PMV in line with the ventilator circuit. Ideally SLT to be present to assess voice quality and upper airway patency.
- Consultant or Senior Physiotherapist should review the ventilator parameters as indicated.
- A nurse competent in ventilator management, tracheostomies and suction (See separate competency) can complete follow-up PMV within the ventilator circuit trials as directed by a weaning plan, they also need to be present throughout the PMV trial if the Physiotherapist or Consultant is not present.
- A professional competent in yankauer and deep suction (See separate competency) should be available throughout.
- The nurse in charge should be aware when PMV within the ventilator circuit trials are taking place if a consultant or Senior Physiotherapist or not present.


Procedure:


- Check patient meets inclusion criteria and there are no contraindications before proceeding.
- Gain agreement from Consultant Team.
- Collect required equipment.
- Ensure appropriate members of staff are present.
- Explain the procedure to patient and check they consent / agree if possible. Advise patient there may be changes to taste/sensation and movement of secretions in the oral cavity. Explain that PMV may not be successful in achieving voice.
- Ensure the patient is sat upright. General care should be taken to not dislodge any lines including NG or NJ tubes.
- Construct the PMV Circuit (FIG1) by attaching the PMV to the 22F end of the catheter mount and a 22F/22F straight connector to the 22M/15F end of the catheter mount
- Yankauer suction in oral cavity / carry out mouth care. If available, use the subglottic aspiration port to remove any secretions from above the cuff prior to cuff deflation. Tracheal suction if required. Pause any feeding pumps.
- With assistance, carry out concurrent tracheostomy suctioning and cuff deflation.
- Repeat oral or tracheostomy suctioning as required to clear any further secretions.
- Allow patient to settle, checking for any immediate changes to observations.
- Check for leak around the tracheostomy by asking the patient to talk or cough.
- Temporarily stop the ventilator, pre-oxygenating if required.
- As per FIG2, disconnect the flexible connector from the closed-circuit suction, remove the flexible connecter from the Y-connector and attach the PMV circuit to the 15mm end of the closed-circuit suction, and the straight connector end to the Y-Connector of the ventilator tubing
- Restart the ventilator.
- Check the patient is tolerating the PMV by observing patient work of breathing and observations. Further suctioning may be required.
- Consider increasing pressure support / Fio2 or reducing PEEP as required to optimise phonation, work of breathing, oxygenation and comfort.
- Adjust alarm settings or switch the ventilator to NIV mode. Pause Co2 monitoring.
- Continue trial as tolerated, observing patient for increased work of breathing or desaturation.

- To finish trial, return ventilator setting and alarms to pre-trial level, returning from NIV mode to invasive ventilation. Stop the ventilator, preoxygenating if required.
- Remove the PMV circuit to reverse FIG2. Replace the flexible connector between the Y-Connector and the 15mm end of the closed-circuit suction. Restart the ventilator.
- Only if PMV is removed, re-inflate the cuff.
- Check patient observations.
- Document outcome of trials in patients notes.

Figures illustrating the construction of the PMV circuit and how it fits within the ventilator circuit







Suitable for printing to guide individual patient management but not for storageReview Due:August 2027 Page 8 of 12

5. Hazards and complications:

Hazard/complication	Action
Reduced oxygen saturations	Increase FiO2 and/or pressure support (PS) to counteract effect or cuff deflation up to the maximum level as stated on the weaning plan.
	Terminate trial if maximum parameters are exceeded
Excessive coughing Complete CCS, terminate if it does not settle	Ensure subglottic and tracheal suction are performed prior to cuff deflation to minimise secretion aspiration.
Patient intolerance	Provide adequate explanation of treatment to reassure patient.
	Increase FiO2 or PS if additional support is required to counteract cuff deflation.
Hyperinflation	Reduce ventilator PEEP to 5cmH2O
De-recruitment following cuff deflation	Increase PS to accommodate cuff leak during trial.
	Provide ventilator recruitment manoeuvres once trial has been completed. Obtain support from the physiotherapy or medical team if required for recruitment manoevres.
Dislodgment or accidental removal of lines including NG or NJ tube.	Medical team to be made aware for re-siting if appropriate.

6. Linked Documents

- Competency document for physiotherapists using a Passy Muir Valve within a ventilator circuit.
- Competency document for nurses using a Passy Muir Valve within a ventilator circuit.
- Nursing competency document for suction, ventilators and tracheostomies

7. References

Batty S (2009). Communication, swallowing and feeding in the intensive care unit patient. Nursing in Critical Care [Online] 14 (4) July-August, pp. 175-179. Available from: .Bier J (2004). Giving your patient a voice with a tracheostomy speaking valve. Nursing 2004 [Online] 34 (1) October, pp. 16-18

Carmona A. F, Díaz M. A, Alonso E. A, Guarasa I. M, López P. M, & Castellanos M. D 2015). Use of speaking valve on preventing respiratory infections in critical traqueostomized patients diagnosed of dysphagia secondary to artificial airway. Edisval study. Intensive Care Medicine Experimental, 3(Suppl 1).

Carrau R, Murry T and Howell R (2016). Comprehensive Management of Swallowing Disorders. 2nd ed. California, Plural Publishing Inc.

Freeman-Sanderson A. L, Togher L, Elkins M. R, & Kenny B (2018). Quality of life improves for tracheostomy patients with return of voice: A mixed methods evaluation of the patient experience across the care continuum. Intensive Critical Care Nursing, 46,10-16.

Gross, RD., Mahlmann, J. and Grayhack, JP. (2003) Physiologic Effects of Open and Closed Tracheostomy Tubes on the Pharyngeal Swallow. Annals of Otology.

Grossbach I, Stranberg S, & Chlan L (2010). Promoting effective communication for patients receiving mechanical ventilation. Critical Care Nurse, 31(3), 46-60.

King, K (2019). Protocols Impacting the Care of Patients with Tracheostomy and Mechanical Ventilation. Passy Muir's Aerodigestive Health, 3 (1), 2-3

Kunduk M, Appel K, Tunc M, Alanoglu Z, Alkis N, Dursun G, Ozgursoy OB (2010).

Preliminary report of laryngeal phonation during mechanical ventilation via a new cuffed tracheostomy tube. Respiratory Care, 55 (12), 1661-1670.

In-Line Passy Muir Valve (PMV) Ventilation Guideline Page 18 of 23

Li J, Perez A, Schehl J, Albers A and Hussain IA (2021) The association between upper airway patency and speaking valve trial tolerance for patients with tracheostomy: A clinical retrospective study and an in vitro study. American Journal of Speech-Language Pathology, 30, 1728-1736.

Magnus V and Turkington L (2006). Communication interaction in ICU-Patient and staff experiences and perceptions: Intensive and Critical Care Nursing, 22, 167-180.

O'Connor LR, Morris N, Paratz JP (2011). The safety and efficacy of prolonged use of one way speaking valves. Australian Critical Care, 34, 319-326.

O'Connor LR, Paratz J, Morris NR (2019) Physiological and clinical outcomes associated with the use of one-way speaking valves in tracheostomised patients: a systematic review.

Heart and lung 48 (4) 356-364. 9PPandian et al. (2014) Optimizing Communication in Ventilated Patients. Journal of Medical

Speech-Language Pathology [Online], 21 (4), pp. 309-318.Passy-Muir® tracheostomy and ventilator swallowing and speaking valves instruction booklet.

https://www.passy-muir.com/wp-content/uploads/2019/08/IB_domestic-R0718.pdf

Sutt and King (2016) In-line Ventilator Application Issue. Talk Muir: Tracheostomy Research, Resources & Information [Online], 6 (1) Fall, pp. 1-24. Available from: http://passymuir.com/newsletter.

Sutt A, Caruana P, Dunster K, Cornwell P (2016). Speaking valves in tracheostomised ICU patients weaning off mechanical ventilation – do they facilitate lung recruitment? Critical Care 20, 91

Sutt A, Anstey CM, Caruana PL, Cornwell PL, Fraser JF (2017). Ventilation distribution and lung recruitment with speaking valve use in tracheostomised patient weaning from mechanical ventilation in intensive care. Journal of Critical Care, 40, 164-170.

Sutt A, Caruana L, Dunster K (2015). Improved lung recruitment and diaphragm mobility with an in-line speaking valve in tracheostomised mechanically ventilated patients – An observational study. Australian Critical Care 28 (1) 45.

Tansley C (2019) Having Protocols for Clinical Use to Improve Patient Outcomes. Passy Muir's Aerodigestive Health, 3 (1), 21-24.

Tembo A, Higgins I and Parker V (2015). The experience of communication difficulties in and beyond intensive care: Findings from a larger phenomenological study. Intensive and Critical Care Nursing [Online], 31 (3) June, pp. 171-178

In-Line Passy Muir Valve (PMV) Ventilation Guideline

8. Documentation Controls (these go at the end of the document but before any appendices)

Reference Number				
Reference Number	Version: 6.6.23	1	Status	Final
CG-CLIN/4445/24			Final	
Version /	Version	Date	Author	Reason
Amendment History	1	26/9/23	Dan Nolan Physiotherapist, Clare Larvin SLT and Nicola Hughes SLTs	No previous guideline in place
Intended Recipients	Speech ar	nd Language	 Therapists, Physic	therapists, Nurses, Doctors
Is this guideline is for Y M	→ Will re		Trust Guideline Group	once divisionally
Development of Guid Daniel Nolan – Clinic Nicola Hughes - Exp Clare Larvin - Specia Consultation with: R SLT tracheostomy g UHDB tracheostomy	al Special erienced S llist SLT espiratory roup	pecialist SL	Т	
Please confirm all releva have pharmacy approva		rs/specialities h	ave been consulted an	d list above eg all drugs must
	,,			
have pharmacy approva Linked Documents: None Keywords:	,,			
have pharmacy approva	 State the na		other relevant doo	
have pharmacy approva Linked Documents: None Keywords: ACV, tracheostomy Business Unit Sign (Divisional Sign Off	,, State the na	ame(s) of any	other relevant doo	acheostomy Group
have pharmacy approva Linked Documents: None Keywords: ACV, tracheostomy Business Unit Sign Off Divisional Sign Off Trust Guideline grou applicable)	,, State the na	ame(s) of any	Group: UHDB tr Date: Group:CDCS Go Date:6/8/2024 Trustwide CGG	acheostomy Group
have pharmacy approva Linked Documents: None Keywords: ACV, tracheostomy Business Unit Sign O Divisional Sign Off Trust Guideline grou applicable) Date of Upload	,, State the na	ame(s) of any	Group: UHDB tr Date: Group:CDCS Go Date:6/8/2024 Trustwide CGG	acheostomy Group
have pharmacy approva Linked Documents: None Keywords: ACV, tracheostomy Business Unit Sign Off Divisional Sign Off Trust Guideline grou applicable)	,, State the na	ame(s) of any	Group: UHDB tr Date: Group:CDCS Go Date:6/8/2024 Trustwide CGG	acheostomy Group